No differences were observed when only the most common mutations in AML (DNMT3, FLT3, NPM1, TET2, RUNX1, IDH1/2, TP53, CEBPA, NRAS, WT1) were considered. This evidence concerns the gene WT1 and acute myeloid leukemia.